Bruce D. Hoechner
the election of Mr. Bruce D. Hoechner as Chair of the Board
Highest-materiality recent filing
Ingevity Q1 net sales $258M (+4%), adj. EPS $1.15 beats $1.01; reaffirms guidance
Net sales $258.0M (+4% YoY); GAAP net income $23.4M ($0.65 diluted EPS) vs $29.1M ($0.79) prior year.
Ingevity sells Ozark Materials road markings business to PPG for $65M
Sold Ozark Materials road markings business to PPG Industries in all-cash deal for ~$65M.
Ingevity refinances revolver: reduces commitments to $750M, extends maturity to 2031
Revolver reduced from $1B to $750M; maturity extended to five years from March 26, 2026.
Full year net sales from continuing ops $1.2B (-3%); net loss $167.1M ($4.61/sh) driven by $293.1M non-cash special charges.
Completed sale of North Charleston CTO refinery and majority of Industrial Specialties to Mainstream Pine Products for $110M cash plus contingent consideration up to $19M.
Completed portfolio review; exploring sale of Advanced Polymer Technologies segment and Performance Chemicals Road Markings business.
Ingevity CFO Hall to step down May 1, 2026; Platt named successor
Mary Dean Hall will transition from CFO to advisor role effective May 1, 2026.
Ingevity provides recast financials reflecting divested businesses as discontinued operations
Divestiture of industrial specialties line and North Charleston CTO Refinery expected to close by early 2026.
Ingevity Q3 total net sales $362.1M (-4% YoY); adj EBITDA $121.2M (+14%); revises FY guidance
Net income $43.5M, EPS $1.18; continuing ops net income $40.8M, EPS $1.10.
All-cash deal: $110M at closing plus up to $19M contingent consideration; expected close by early 2026.
Ingevity posts Q2 net loss of $146.5M on $183.8M goodwill impairment; adjusted EPS up 38% to $1.39
Net sales $365.1M, down 7% YoY, led by lower Performance Chemicals volumes.
Ingevity Q1: adjusted EBITDA $91.3M (+23%); sales $284M (-17%); FY guidance revised
Net sales $284.0M, down 17% YoY, due to Performance Chemicals repositioning and exit of lower-margin markets.
Ingevity expands board to 11; elects new CEO Li and Segal; Hoechner named Chair
Board increased from 9 to 11; David H. Li (President & CEO) and F. David Segal elected directors.
Ingevity settles proxy contest with Vision One; appoints F. David Segal to board
Cooperation agreement appoints F. David Segal to board and audit committee within one day of 2025 annual meeting.
Ingevity appoints David H. Li as CEO; $1.1M base salary, $5M one-time equity award
David H. Li appointed President and CEO effective April 7, 2025, succeeding interim CEO Luis Fernandez-Moreno who remains on board.
Ingevity Q4 net sales down 20% YoY to $298.8M; full-year net loss $430.3M
Q4 net sales $298.8M (-20% YoY); adjusted EBITDA $80.6M (margin 27.0%); net income $16.6M includes $23.4M restructuring charges.
Ingevity explores sale of Industrial Specialties line; prelim FY2024 sales $1.40B, EBITDA ~$360M
Exploring strategic alternatives for Performance Chemicals Industrial Specialties product line, including potential divestiture of North Charleston CTO refinery.
Ingevity Q3 net loss $107.2M; sales down 16% YoY; affirms FY adjusted EBITDA guidance
Net sales $376.9M, down 16% YoY, primarily due to Performance Chemicals repositioning.
Ingevity CEO John Fortson departs; board member Luis Fernandez-Moreno named interim CEO
John Fortson resigned as President, CEO, and board member effective October 2, 2024.
Ingevity to close Crossett, AR plant; expects $30-35M annual savings from restructuring
Plans to close Crossett plant in August 2024; consolidate oleo refining to North Charleston, SC facility.
Ingevity Q2 net loss $283.7M on goodwill impairment; guides FY sales $1.40-1.50B
Net sales $390.6M, down 19% YoY; net loss of $283.7M ($7.81 diluted EPS) due to Performance Chemicals goodwill impairment.
Ingevity pays $100M to terminate crude tall oil supply agreement with Georgia-Pacific
Paid $50M on July 1, 2024; second $50M installment due Oct 15, 2024 to terminate 20-year CTO supply pact.
Ingevity Q1 2024 net loss of $56M, sales down 13%; reiterates full-year guidance
Net sales $340.1M, down 13% YoY; net loss $56.0M ($1.54 diluted EPS loss).
Ingevity Q4 net loss of $116.8M includes $107.5M restructuring; FY2024 sales guidance $1.40-1.55B
Q4 net sales $371.7M (-3.1% YoY); net loss $116.8M, diluted loss per share $3.23.
the election of Mr. Bruce D. Hoechner as Chair of the Board
the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board
the election of Mr. David H. Li and Mr. F. David Segal to fill the vacancies created by the expansion of the Board
On March 10, 2025, Ingevity Corporation (“Ingevity”) announced that its Board of Directors (the “Board”) has appointed David H. Li as President and Chief Executive Officer of Ingevity, effective April 7, 2025
In connection with Mr. Li’s appointment, Luis Fernandez-Moreno will step down as interim President and Chief Executive Officer of Ingevity as of the Effective Date.
He succeeds John C. Fortson, who departed as President and Chief Executive Officer and has resigned as a member of the Board, effective as of October 2, 2024.
the Board has appointed Luis Fernandez-Moreno as the interim President and Chief Executive Officer of the Company
He succeeds John C. Fortson, who departed as President and Chief Executive Officer and has resigned as a member of the Board, effective as of October 2, 2024.
Ryan C. Fisher, previously the Company’s Vice President, Deputy General Counsel and Chief Compliance Officer, has been appointed Senior Vice President, General Counsel and Secretary of the Company.
On June 26, 2024, Stacy L. Cozad notified Ingevity Corporation (the “Company”) of her decision to resign as Executive Vice President, General Counsel and Secretary of the Company, which resignation took effect as of such date.
On March 12, 2024, William J. Slocum informed the Nominating & Governance Committee of the Board of Directors (the “Board”) of Ingevity Corporation (the “Company”) of his resignation from the Board effective as of March 13, 2024 at 5:00 p.m.
Max materiality 0.85 · Median 0.70 · Most common event earnings